References
- Barouch DH, Liu J, Li H et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482(7383), 89–93 (2012).
- Esparza J, Russell N, Gayle H et al. The challenge of developing an HIV vaccine. In: HIV Vaccine Research and Development in Thailand. Pitisuttithum P, Francis DP, Esparza J et al. (Eds). Mahidol University, Bangkok, Thailand, 3–26 (2006).
- Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 455(7213), 613–619 (2008).
- Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191(5), 654–665 (2005).
- Pitisuttithum P, Gilbert P, Gurwith M et al.; Bangkok Vaccine Evaluation Group. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194(12), 1661–1671 (2006).
- Freel SA, Saunders KO, Tomaras GD. CD8+ T-cell-mediated control of HIV-1 and SIV infection. Immunol. Res. 49(1–3), 135–146 (2011).
- Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881–1893 (2008).
- Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al.; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209–2220 (2009).
- Haynes BF, Gilbert PB, McElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366(14), 1275–1280 (2012).
- Johnston MI, Fauci AS. An HIV vaccine – evolving concepts. N. Engl. J. Med. 356(20), 2073–2081 (2007).
- Burton DR, Desrosiers RC, Doms RW et al. Public health. A sound rationale needed for Phase III HIV-1 vaccine trials. Science 303(5656), 316 (2004).
- Letvin NL, Rao SS, Montefiori DC et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med. 3(81), 81ra36 (2011).
- Keele BF, Li H, Learn GH et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206(5), 1117–1134 (2009).
- Kwong PD, Mascola JR, Nabel GJ. Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1. Cold Spring Harb. Perspect. Med. 1(1), a007278 (2011).
- DeVico A, Fouts T, Lewis GK et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc. Natl Acad. Sci. USA 104(44), 17477–17482 (2007).
- Sun Y, Asmal M, Lane S et al. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J. Virol. 85(14), 6906–6912 (2011).
- Walker BD, Ahmed R, Plotkin S. Use both arms to beat HIV. Nature Med. 17(10), 1194–1195 (2011).